Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: Tolerability and clinical events

AIDS

Volumn 22, Issue 1, 2008, Pages 67-74

  Hoffmann, Christopher J ^a,b   Fielding, Katherine L ^c   Charalambous, Salome ^a   Sulkowski, Mark S ^b   Innes, Craig ^a   Thio, Chloe L ^b   Chaisson, Richard E ^b   Churchyard, Gavin J ^a,c,d   Grant, Alison D ^c  

^a AURUM INSTITUTE   (South Africa)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; HEMOGLOBIN; ISONIAZID; LAMIVUDINE; LIVER ENZYME; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BODY BUILD; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; DEATH; DIZZINESS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEALTH STATUS; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LABORATORY TEST; LACTIC ACIDOSIS; LIVER TOXICITY; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SOUTH AFRICA; STATISTICAL SIGNIFICANCE; VOMITING;

ADULT; ANEMIA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; COHORT STUDIES; DEVELOPING COUNTRIES; DIZZINESS; DRUG TOLERANCE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PROSPECTIVE STUDIES; SOUTH AFRICA; TREATMENT OUTCOME; VIRAL LOAD; VOMITING; ZIDOVUDINE;

EID: 37349036173     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f2306e     Document Type: Article

References (25)

1. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 3 by 5, 1st ed. Geneva, Switzerland: World Health Organization; 2002.
2. Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001; 33:1914-1921.
3. Anekthananon T, Ratanasuwan W, Techasathit W, Suwanagool S, Auwanit W. 76 Weeks study of safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine, and nevirapine for the treatment of advanced HIV-infected patients. In: 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; 24-27 July 2006. Abstract TuPe11.8C08.
4. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335-1342.
5. Geddes R, Knight S, Moosa MY, Reddi A, Uebel K, Sunpath H. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006; 96:722-724.
6. Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, et al. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 2005; 40:65-69.
7. Kimani DK, Filen F, Nderitu M, Van Engelgem I, Suleh A, Zachariah R. Characteristics and outcomes of patients with symptomatic hyperlactatemia, on a first-line antiretroviral regimen of stavudine, lamivudine, and nevirapine in an urban district hospital setting in Kenya. In: XVIth International AIDS Conference. Toronto, Canada; 13-18 August 2006. Abstract WePe0150.
8. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access, 2006 revision. Geneva, Switzerland: World Health Organization; 2006.
9. Charalambous S, Grant AD, Day JH, Pemba L, Chaisson RE, Kruger P, et al. Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care 2007; 19:34-41.
10. AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases; 1996.
11. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
12. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308.
13. Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, Anastos K, et al. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 37:1245-1252.
14. Huang SS, Barbour JD, Deeks SG, Huang JS, Grant RM, Ng VL, McCune JM. Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis 2000; 30:504-510.
15. Moyle G, Sawyer W, Law M, Amin J, Hill A. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther 2004; 26:92-97.
16. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 2005; 10:615-624.
17. Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 2000; 14:1591-1600.
18. Levine AM, Karim R, Mack W, Gravink DJ, Anastos K, Young M, et al. Neutropenia in human immunodeficiency virus infection: data from the Women's Interagency HIV Study. Arch Intern Med 2006; 166:405-410.
19. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol 1996; 49:664-666.
20. Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, Langeland N, et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol 2004; 11:29-34.
21. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4:543-555.
22. Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003; 4:62-66.
23. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714-721.
24. Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367:1256-1261.
25. Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, Sinyinza F, et al. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 2007; 21:77-84.